|
⚲
|
| Keyboard |
| Moderna Inc | |
|---|---|
| Ticker | MRNA |
| CIK # | 0001682852 |
| CUSIP | 56804Q201 |
| Sector | Life Sciences - Biological Products, (No Disgnostic Substances) |
| Address | 200 Technology Square, Cambridge, MA 02139 |
| Source | [EDGAR] |
| Reg D Offering (Form D) | Filed | Raised | Terms |
|---|---|---|---|
| Moderna Therapeutics Inc | 2016-08-24 | 451.4 M | Exemption: 506(b) · Remaining: $148,630,913 · Duration: One year or less · Revenue: Decline to Disclose |
| CIK | Filing | 2011 - 2026 |
|---|---|---|
| [0001682852] | 10-K | |
| [0001682852] | 10-Q | |
| [0001682852] | 3 | |
| [0001682852] | 4 | |
| [0001682852] | 5 | |
| [0001682852] | 8-K | |
| [0001682852] | D | |
| [0001682852] | SC 13G |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed | % Owned |
|---|---|---|---|
| Vanguard Capital Management LLC | Moderna Inc | [2026-04-30] | 0.0 |
| FMR LLC | Moderna Inc | [2026-02-05] | 0.0 |
| FMR LLC | Moderna Inc | [2025-05-12] | 0.0 |
| BlackRock Inc | Moderna Inc | [2022-02-04] | 6.8 |
| BlackRock Inc | Moderna Inc | [2021-02-02] | 5.2 |
| Baillie Gifford & Co | Moderna Inc | [2021-01-27] | 6.14 |
| Vanguard Group Inc | Moderna Inc | [2020-02-11] | 5.19 |
| Bancel Stephane | Moderna Inc | [2019-02-14] | 0.3 |
| Springer Timothy A | Moderna Inc | [2019-02-14] | 4.0 |
| Flagship Ventures Fund IV General Partner LLC | Moderna Inc | [2019-02-12] | 3.48 |
| Astrazeneca PLC | Moderna Inc | [2019-01-30] | 7.75 |
| Viking Global Investors LP | Moderna Inc | [2018-12-21] | 5.2 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Mock James M
Restricted Stock Units · derivative
|
2026-03-05 | Option exercise | 11,797 | $0.00 | |
|
Mock James M
Common Stock
|
2026-03-05 | Tax withheld | 5,704 | $57.80 | 329,691 |
|
Klinger Shannon Thyme
Common Stock
|
2026-03-05 | Tax withheld | 5,704 | $57.80 | 329,691 |
|
Mock James M
Common Stock
|
2026-03-05 | Option exercise | 11,797 | ||
|
Klinger Shannon Thyme
Common Stock
|
2026-03-05 | Option exercise | 11,797 | ||
|
Klinger Shannon Thyme
Restricted Stock Units · derivative
|
2026-03-05 | Option exercise | 11,797 | $0.00 | |
|
Klinger Shannon Thyme
Stock Option (Right to Buy) · derivative
|
2026-03-02 | Option exercise | 13,885 | $0.00 | |
|
Klinger Shannon Thyme
Common Stock
|
2026-03-02 | Option exercise | 13,885 | $30.96 | 429,880 |
|
Klinger Shannon Thyme
Common Stock
|
2026-03-02 | Sell | 13,885 | $52.29 | 726,047 |
|
Mock James M
Restricted Stock Units · derivative
|
2026-03-01 | Grant | 49,569 | $0.00 | |
|
Klinger Shannon Thyme
Restricted Stock Units · derivative
|
2026-03-01 | Grant | 38,553 | $0.00 | |
|
Hoge Stephen
Stock Option (Right to Buy) · derivative
|
2026-03-01 | Grant | 125,466 | $0.00 | |
|
Klinger Shannon Thyme
Stock Option (Right to Buy) · derivative
|
2026-03-01 | Grant | 29,275 | $0.00 | |
|
Hoge Stephen
Restricted Stock Units · derivative
|
2026-03-01 | Grant | 165,230 | $0.00 | |
|
Mock James M
Stock Option (Right to Buy) · derivative
|
2026-03-01 | Grant | 37,639 | $0.00 | |
|
Bancel Stephane
Stock Option (Right to Buy) · derivative
|
2026-03-01 | Grant | 250,932 | $0.00 | |
|
Klinger Shannon Thyme
Restricted Stock Units · derivative
|
2026-02-27 | Option exercise | 233 | $0.00 | |
|
Mock James M
Common Stock
|
2026-02-27 | Option exercise | 774 | ||
|
Klinger Shannon Thyme
Restricted Stock Units · derivative
|
2026-02-27 | Option exercise | 774 | $0.00 | |
|
Mock James M
Common Stock
|
2026-02-27 | Option exercise | 9,901 | ||
| showing 20 of 200 most recent transactions | |||||
| 13F Ownership Over Time | Holders | Shares Held |
|---|---|---|
| 2026-03-31 | 739 | 366,338,779 |
| 2025-12-31 | 688 | 388,249,952 |
| 2025-09-30 | 655 | 358,289,731 |
| 2025-06-30 | 682 | 355,413,366 |
| 2025-03-31 | 708 | 335,207,471 |
| 2024-12-31 | 762 | 316,650,027 |
| 2024-09-30 | 808 | 288,839,618 |
| 2024-06-30 | 977 | 280,743,149 |
| 2024-03-31 | 918 | 292,867,262 |
| 2023-12-31 | 905 | 286,181,429 |
| 2023-09-30 | 900 | 264,618,420 |
| 2023-06-30 | 979 | 259,062,646 |